Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options? | Zendy

Alison R. Novak | Zendy; Mary E. Bradley | Zendy; Tyree H. Kiser | Zendy; Scott W. Mueller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options?

Author(s) -

Alison R. Novak,

Mary E. Bradley,

Tyree H. Kiser,

Scott W. Mueller

Publication year - 2020

Publication title -

current fungal infection reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.413

H-Index - 24

eISSN - 1936-377X

pISSN - 1936-3761

DOI - 10.1007/s12281-020-00379-2

Subject(s) - echinocandin , posaconazole , azole , echinocandins , amphotericin b , intensive care medicine , aspergillus fumigatus , aspergillosis , medicine , antifungal , caspofungin , biology , fluconazole , microbiology and biotechnology , immunology

This review summarizes current treatment options for echinocandin-resistant Candida spp. (ERC) and azole-resistant Aspergillus fumigatus (ARAF), emphasizing recent in vitro/in vivo data, clinical reports, and consensus statements.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research